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graft required for transplantation to remain cost saving compared to dialysis; the 
number of future transplants or improvement in graft survival required to avoid the 
transplant waiting list increasing. The study utilises UK costs and future costs and 
benefits were discounted at 3.5% Results: Over a 10-year projected time horizon 
the total per-patient cost saving associated with remaining on dialysis compared 
to transplant was £276,330; however, a cost saving was conditional upon achieving 
at least 3-years of functioning graft. In order to maintain the transplant waiting list 
at approximately 7,000, the number of annual transplants conducted would need to 
increase from 2,645 in 2010 to 3,640 by 2022 (a 37.6 % increase). At current activity 
levels the transplant waiting list is projected to increase by approximately 1,983; 
improvement in graft survival could potentially reduce this by 941. ConClusions: 
For kidney transplantation to be cost saving recipients must maintain at least 3 
years of functioning graft. As early graft failure also impacts on future transplant 
waiting time, management strategies that maximize graft survival will reduce costs 
and improve service delivery targets.
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objeCtives: Economic evaluations require patient-level resource-use to estimate 
patient costs. The National Programme for IT (2002) prompted UK health and 
social care to record patient-level resource-use using Electronic Administration 
Records (EAR’s). Retrieving EAR’s is labour intensive, but may provide better infor-
mation than self-report methods, such as the Client Service Receipt Inventory 
(CSRI), particularly in cognitively impaired people. Study objectives are to examine 
agreement, and associated cost estimates, between resource-use obtained from 
EAR's or CSRI in frail older (≥70) participants. Methods: Health and social care 
data for 247 patients (193 cognitively impaired) were sought retrospectively six 
months post-index hospital admission. Resource-use data were collected using 
a self/proxy-reported modified CSRI, and EAR systems for primary (PC), second-
ary (SC), and social (SoC) care. Lin’s coefficient (ρc) assessed agreement between 
methods, where <0.4 = poor agreement. Results: Agreement between EAR and 
CSRI ‘per contact’ resource-use was: good, primary care (ρc = 0.60); fair, outpa-
tient care (ρc = 0.53). Agreement was incomparable for social care due to different 
resource-use recording formats; CSRI’s inpatient care question was removed due 
to the preferred detailed information available in EAR’s. EAR data provided detailed 
patient care information, such as diagnosis and procedure type, allowing improved 
allocation of unit costs. Difference in mean cost per patient between methods 
varied by service (CSRI/EAR (£): PC = 61/433; SC = 7281/7833; SoC = 252/886); CSRI 
inpatient costs were simulated assuming perfect agreement with EAR, but using 
level of information outlined within the CSRI. ConClusions: EAR’s provided 
more complete patient costs. Using EAR’s reduces burden upon participants, which 
is important for frail and cognitively impaired people. Although the CSRI can be 
modified and simple to administer, poor recall and inadequate detail about patient 
care contacts prevented accurate patient-level cost estimation. Gaining access to 
EAR’s is labour intensive, but recommended in cognitively impaired participants.
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objeCtives: The cost-effectiveness of pertussis vaccination has been demonstrated 
for various vaccination strategies. However, beyond financial cost expressed in mon-
etary terms vaccines also incur environmental cost expressed in CO2equivalent 
(CO2e) emission. By preventing disease, this cost might be offset by avoided events 
such as doctors’ visits, hospital bed stays, medication, amongst other items. In 
this exercise we examine the CO2e savings of a pertussis (dTpa) booster dose for 
cocooning in England and Wales. We propose a complementary measure to the 
classical Incremental Cost-Effectiveness Ratio that includes environmental cost 
instead of monetary cost. Methods: The cradle to gate carbon footprint (from 
raw material extraction, to manufacturing, to disposal) for a typical dTpa vaccine 
dose was assessed to estimate the total amount of CO2e emitted (“carbon cost”). 
A previously published static epidemiological model was used to account for the 
reduction in incidence of pertussis. Two scenarios were compared: the current per-
tussis vaccination schedule and the same schedule with additionally a cocooning 
strategy. Results: For each dose of a dTpa vaccine manufactured, results show 
approximately 1kg of CO2e was emitted. The model shows cocooning immuniza-
tion against pertussis is projected to reduce the reported incidence of pertussis in 
young infants. Results also show that due to the reduction in emitted CO2e after 
the introduction of a cocooning strategy, vaccination is an acceptable alternative 
to the current strategy to control pertussis infection. ConClusions: The method 
presented demonstrates how traditional economic models can be utilized to model 
environment features. Assessment of the cradle to gate carbon footprint of a vaccine 
provides a preliminary view of both the impact on the environmental in general 
and on the environment profile of health care in the UK.
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objeCtives: In 2012, NICE initiated a multiple treatment assessment reviewing all 
licensed biologics for the treatment of rheumatoid arthritis (RA) previously treated 
experienced and high-quality source for post-approval studies. Elaborated manage-
ment processes in multi-country panels guarantee a constant quality of the panel 
over geographies.
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objeCtives: Cognitive functioning is a multidimensional attribute comprising 
various domains including attention, memory, executive function, and psycho-
motor speed. The number of impacted domains and magnitude of deficits that 
equate to a classification of cognitive dysfunction (CD) are unclear. This analysis 
examined criteria used for CD classification in an observational study of depressed 
patients. Methods: A large US health plan was used to identify depressed patients 
with a newly prescribed antidepressant. Consenting, eligible patients were inter-
viewed by telephone and completed a structured assessment of cognitive function 
measuring 4 domains: verbal episodic memory (Hopkins Verbal Learning Test-
Revised), attention (Digit Span Forward), working memory (Digit Span Backward), 
and executive function (D-KEFS-Letter Fluency Test). Patients were classified into 2 
groups based on test scores relative to normative data. “CD” was defined as patients 
with ≥ 2 scores that were ≥ 1.5 standard deviations (SD) below the normative mean 
(criterion 1) or patients with ≥ 3 scores that were ≥ 1.0 SD below the normative 
mean (criterion 2). Patients not meeting either of these were classified as “cognitive 
normal (CN).” T-tests compared differences between the groups across cognitive 
domains. Results: Of 564 eligible patients who completed the study, 45% met 
criteria for CD. Among these, 63% met both criteria for classification of CD, 19% met 
only criterion 1, and 18% met only criterion 2. The percentage of patients with scores 
≥ 1.0 SD below the mean and ≥ 1.5 SD below the mean were significantly higher in the 
CD group compared to the CN for all 4 tests. Mean scores on all domains were signifi-
cantly lower (P < 0.001) in the CD group compared to the CN group. ConClusions: 
Among patients with depression, those with cognitive dysfunction had significantly 
worse functioning across all domains. This suggests that the criteria appropriately 
identified a subset of patients with impaired cognitive functioning.
ReseaRCh on Methods – Cost Methods
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objeCtives: Adequate reflection of disease progression and costs over time is 
essential in cost-effectiveness analyses (CEAs) based on health state transition mod-
els. However costing studies normally investigate the burden of metastatic breast 
cancer (MBC) without explicitly examining impact of specific disease states on 
health care costs over time. The objective of this study was to assess time-dependent 
costs of different health states of human epidermal receptor 2 (HER-2) positive 
MBC and the factors contributing to these costs. Methods: In The Netherlands, 
HER-2 positive MBC patients were identified in three different hospitals. Resource 
use was collected during 24 months, which was linked to unit costs and related 
to time with respect to date of MBC diagnosis, disease progression and death for 
each individual patient. Subsequently, monthly costs for different health states 
were calculated. Finally, a nonlinear mixed effect modelling approach was used 
to provide a quantitative description of the time course of cumulative progression 
costs. Results: Costs during stable disease were constant over time with a mean 
of € 3,236. In contrast, monthly costs for progressive disease demonstrated a change 
over time with the largest costs in the first two months after diagnosis (p< 0.005). The 
developed mixed effect model adequately described cumulative cost time course 
and associated variability. During the last months of life, costs varied over time, with 
the last month of life as the most expensive one with a mean of € 4,522 per patient 
per month. ConClusions: To reflect costs of HER-2 positive MBC accurately in 
Markov models, costs stable disease can be defined time-independent, however, 
costs of progressive disease should be defined time dependent, and costs related to 
the final months of life should be modeled as such. The mixed effect model we have 
developed could now be considered for adequate description of the time-dependent 
cost of progressive disease.
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objeCtives: The UK has an ageing and growing population and the prevalence 
of renal replacement therapy (RRT) has grown by 5.0% annually since 2000. RRT 
accounts for over 2% of the current NHS expenditure. Transplantation increases 
survival, improves quality of life and maintenance costs are less than dialysis. 
Despite increasing rates of transplantation, an estimated 7,000 patients remain 
on the waiting list. The objective of this study was to quantify the relationship 
between graft survival time, total estimated cost and the number of projected 
patients on the transplant waiting list. Methods: We utilized a population based 
simulation model with published disease progression, incidence and prevalence 
parameters specific to the UK. We evaluated the number of years of functioning 
